Prediction of immune related adverse events by genetic analysis

Prediction of immune related adverse events by genetic analysis - Prediction of irAE by genetics

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026047

Enrollment

300

Registered

2017-02-08

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant melanoma, lung cancer, renal cancer, Hodgkin lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients receiving immune checkpoint blockade therapy

Exclusion criteria

Exclusion criteria: Patients under clinical trial

Design outcomes

Primary

Measure	Time frame
Immune related adverse event	—

Secondary

Measure	Time frame
efficacy of the treatment	—

Countries

Japan

Contacts

Public ContactYohei Kirino

Yokohama City University Graduate School of Medicine Department of Stem Cell and Immune Regulation

kirino@yokohama-cu.ac.jp+81-45-787-2800

Outcome results